Gilead Sciences (NASDAQ:GILD) Given New $190.00 Price Target at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) had its price target hoisted by stock analysts at Wells Fargo & Company from $165.00 to $190.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “overweight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s target price suggests a potential upside of 10.40% from the company’s current price.

A number of other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday. Bank of America lifted their target price on shares of Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, UBS Group restated a “buy” rating on shares of Gilead Sciences in a research report on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $163.96.

Gilead Sciences Stock Up 3.9%

NASDAQ:GILD traded up $6.50 on Friday, hitting $172.11. 4,513,284 shares of the company’s stock were exchanged, compared to its average volume of 6,782,397. The firm has a 50-day moving average price of $150.33 and a 200-day moving average price of $139.55. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $175.65. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a market cap of $213.40 billion, a P/E ratio of -64.56 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. During the same quarter last year, the company earned $2.47 EPS. Gilead Sciences’s revenue for the quarter was up 6.8% compared to the same quarter last year. As a group, analysts expect that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This represents a 58.26% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the sale, the chief executive officer directly owned 577,133 shares in the company, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 111,000 shares of company stock worth $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of Gilead Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Integrity Alliance LLC. grew its holdings in Gilead Sciences by 9.6% during the 3rd quarter. Integrity Alliance LLC. now owns 5,080 shares of the biopharmaceutical company’s stock worth $757,000 after acquiring an additional 445 shares during the period. Integrity Advisory Solutions LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at about $207,000. First Nebraska Trust Co acquired a new stake in Gilead Sciences during the third quarter worth approximately $567,000. Aware Super Pty Ltd as trustee of Aware Super increased its holdings in Gilead Sciences by 15.1% in the third quarter. Aware Super Pty Ltd as trustee of Aware Super now owns 135,254 shares of the biopharmaceutical company’s stock worth $20,160,000 after purchasing an additional 17,771 shares in the last quarter. Finally, Tucker Asset Management LLC lifted its stake in Gilead Sciences by 5.2% in the third quarter. Tucker Asset Management LLC now owns 4,175 shares of the biopharmaceutical company’s stock valued at $622,000 after buying an additional 205 shares during the period. Institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly results exceeded expectations: Gilead reported third-quarter revenue of $8.3 billion, up 6.8% year over year and approximately $500 million above consensus. Non-GAAP EPS of $2.55 also surpassed estimates of roughly $2.17–$2.19. Gilead Sciences Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: 2026 sales outlook was raised: Management now expects full-year product sales of approximately $31.0 billion to $31.3 billion, up from $30.1 billion to $30.4 billion, reflecting strong HIV demand and broader base-business growth. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: Growth beyond Biktarvy was encouraging: Trodelvy sales rose 41.7% year over year to $506 million, while management highlighted strong performance across its HIV portfolio. Gilead also agreed to acquire PepStar’s oral IL-23R inhibitor program for $1.275 billion upfront, supporting its future pipeline. Gilead Sciences Why I Remain Bullish After Q3
• Positive Sentiment: Analyst support improved: Needham raised its price target to $200 and maintained a Buy rating, while Cantor Fitzgerald increased its target to $175 and kept an Overweight rating after the earnings report. Analysts Increase Forecasts on Gilead Sciences
• Neutral Sentiment: Gilead secured a pan-Canadian reimbursement agreement for LYVDELZI, potentially expanding access to the primary biliary cholangitis treatment. The company also declared a quarterly dividend of $0.82 per share.
• Negative Sentiment: Longer-term pricing pressure remains: Management said Medicare pricing changes are expected to reduce Biktarvy’s price by about 38% beginning in 2028, creating an estimated $1.5 billion annual revenue headwind. The company also lowered or widened its 2026 EPS outlook, and some analysts cautioned that third-quarter HIV growth benefited from temporary inventory and channel effects. Gilead Hikes 2026 Sales Outlook
• Negative Sentiment: Gilead agreed to pay $45 million to settle Texas allegations involving unlawful incentives to healthcare providers, adding a legal and compliance expense.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.